{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:45:41Z","timestamp":1793857541102,"version":"4.6.1"},"reference-count":67,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Lupus"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:p>\n                    <jats:bold>Objective<\/jats:bold>\n                    : Intravenous immunoglobulins (IVIG) are an established treatment in several immune-mediated diseases such as dermatomyositis or Kawasaki disease and they have been used in distinct clinical scenarios in systemic lupus erythematosus (SLE). However, in this latter disease no clear evidence besides hematological or renal involvement supports its use. The aim of the present study is to establish evidence for the treatment of non-renal non-hematological lupus with IVIG.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods<\/jats:bold>\n                    : We have carried out a systematic literature review following PRYSMA principles on the use of this treatment in SLE patients with no renal no hematologic manifestations.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    : We found 35 articles which were split into two subtypes, those with individualized data (29) and those with grouped data. Overall, 198 lupus patients treated with IVIGs [178 (90%) women and 20 (10%) men] were included. In 167 (84.3%) a clinical response was obtained [62 (31.3%) complete and 105 (53%) a partial one]. Adverse events were reported in 40 patients (20.2%), most of them mild with only 2 (1%) severe. According to individualized data, all cases with respiratory problems (5), 82.4% of those with cardiac involvement (18) and 53.8% of those with neuropsychiatric manifestations (18) achieved a complete response as more outstanding results.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions<\/jats:bold>\n                    : After reviewing the experience of the use of IVIGs in extra-renal and extra-hematologic SLE patients, this treatment is demonstrated to be useful in refractory cases, especially in pulmonary, cardiac or neuropsychiatric complications with a good safety profile.\n                  <\/jats:p>","DOI":"10.1177\/09612033251319402","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T18:51:47Z","timestamp":1738867907000},"page":"261-269","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Systematic literature review of intravenous immunoglobulin use in non-renal and non-hematologic systemic lupus erytehmatosus"],"prefix":"10.1177","volume":"34","author":[{"given":"Cristina","family":"Primo-Gabriel","sequence":"first","affiliation":[{"name":"School of Medicine, Universidad del Pa\u00eds Vasco, Vitoria-Gasteiz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Garc\u00eda-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital Universitario Araba, Vitoria-Gasteiz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9378-8412","authenticated-orcid":false,"given":"Jaime","family":"Calvo-Al\u00e9n","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad del Pa\u00eds Vasco, Vitoria-Gasteiz, Spain"},{"name":"Department of Rheumatology, Hospital Universitario Araba, Vitoria-Gasteiz, Spain"},{"name":"Bioaraba Health Research Institute, Vitoria-Gasteiz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra993360"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000086"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.4.367"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp050282"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0249"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp050283"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/antib12010020"},{"key":"e_1_3_4_9_2","first-page":"3523057","article-title":"Intravenous immunoglobulins: mode of action and indications in autoimmune and inflammatory dermatoses","volume":"2016","author":"Dourmishev LA","year":"2016","unstructured":"Dourmishev LA, Guleva DV, Miteva LG. Intravenous immunoglobulins: mode of action and indications in autoimmune and inflammatory dermatoses. Int J Inflamm 2016; 2016: 3523057.","journal-title":"Int J Inflamm"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2565(03)71352-6"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103182"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_4_13_2","unstructured":"Critical-appraisal-tools - critical appraisal tools | Joanna Briggs Institute."},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V5101746"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1159\/000187100"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002960000053"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-009-8162-x"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00319968"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/pde.13015"},{"issue":"6","key":"e_1_3_4_20_2","first-page":"1018","article-title":"Successful intravenous immunoglobulin treatment for steroid-resistant eosinophilic enteritis in a patient with systemic lupus erythematosus","volume":"29","author":"Ciccia F","year":"2011","unstructured":"Ciccia F, Giardina AR, Alessi N, et al. Successful intravenous immunoglobulin treatment for steroid-resistant eosinophilic enteritis in a patient with systemic lupus erythematosus. Clin Exp Rheumatol 2011; 29(6): 1018\u20131020.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-007-0190-z"},{"issue":"3","key":"e_1_3_4_22_2","first-page":"495","article-title":"Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: report of 2 cases","volume":"20","author":"Winder A","year":"1993","unstructured":"Winder A, Molad Y, Ostfeld I, et al. Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: report of 2 cases. J Rheumatol 1993; 20(3): 495\u2013498.","journal-title":"J Rheumatol"},{"issue":"10","key":"e_1_3_4_23_2","first-page":"1635","article-title":"Lupus refractory pleural effusion: transient response to intravenous immunoglobulins","volume":"18","author":"Ben-Chetrit E","year":"1991","unstructured":"Ben-Chetrit E, Putterman C, Naparstek Y. Lupus refractory pleural effusion: transient response to intravenous immunoglobulins. J Rheumatol 1991; 18(10): 1635\u20131637.","journal-title":"J Rheumatol"},{"issue":"3","key":"e_1_3_4_24_2","first-page":"295","article-title":"Use of high-dose intravenous immunoglobulin in systemic lupus erythematosus: report of three cases","volume":"7","author":"Corvetta A","year":"1989","unstructured":"Corvetta A, Della Bitta R, Gabrielli A, et al. Use of high-dose intravenous immunoglobulin in systemic lupus erythematosus: report of three cases. Clin Exp Rheumatol 1989; 7(3): 295\u2013299.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.3109\/03009749009092628"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-004-0931-6"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s100670050091"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2016.05.005"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.058784"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0000000000000232"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-1098-x"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025591"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00124743-199908000-00010"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s100670050079"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-004-1046-9"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1994.00540200108024"},{"issue":"12","key":"e_1_3_4_37_2","first-page":"763","article-title":"Intravenous immunoglobulin for pediatric neuropsychiatric lupus triggered by Epstein-Barr Virus cerebral infection","volume":"18","author":"Brogna C","year":"2016","unstructured":"Brogna C, Manna R, Contaldo I, et al. Intravenous immunoglobulin for pediatric neuropsychiatric lupus triggered by Epstein-Barr Virus cerebral infection. Isr Med Assoc J 2016; 18(12): 763\u2013766.","journal-title":"Isr Med Assoc J"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309351539"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.21cr02969"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.3109\/03009749609080011"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu464cr"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(89)90198-X"},{"issue":"1","key":"e_1_3_4_43_2","first-page":"55","article-title":"Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases","volume":"10","author":"Sherer Y","year":"2008","unstructured":"Sherer Y, Kuechler S, Jose Scali J, et al. Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. Isr Med Assoc J 2008; 10(1): 55\u201357.","journal-title":"Isr Med Assoc J"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.11.1301"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1177\/096120339700600414"},{"issue":"1","key":"e_1_3_4_46_2","first-page":"71","article-title":"High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study","volume":"23","author":"Schroeder JO","year":"1996","unstructured":"Schroeder JO, Zeuner RA, Euler HH, et al. High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. J Rheumatol 1996; 23(1): 71\u201375.","journal-title":"J Rheumatol"},{"issue":"2","key":"e_1_3_4_47_2","first-page":"163","article-title":"Long-term i.v. Ig treatment in systemic lupus erythematosus","volume":"12","author":"Francioni C","year":"1994","unstructured":"Francioni C, Galeazzi M, Fioravanti A, et al. Long-term i.v. Ig treatment in systemic lupus erythematosus. Clin Exp Rheumatol 1994; 12(2): 163\u2013168.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"e_1_3_4_48_2","first-page":"41","article-title":"Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a series of 52 patients from a single centre","volume":"32","author":"Camara I","year":"2014","unstructured":"Camara I, Sciascia S, Simoes J, et al. Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a series of 52 patients from a single centre. Clin Exp Rheumatol 2014; 32(1): 41\u201347.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.3109\/03009749409103065"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330825"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.51.10.1149"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2020.1817479"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2016.06.004"},{"issue":"4","key":"e_1_3_4_54_2","first-page":"CD002936","article-title":"Intravenous immunoglobulins for multiple sclerosis","volume":"2003","author":"Gray O","year":"2003","unstructured":"Gray O, McDonnell GV, Forbes RB. Intravenous immunoglobulins for multiple sclerosis. Cochrane Database Syst Rev 2003; 2003(4): CD002936.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000256698.69121.45"},{"issue":"1","key":"e_1_3_4_56_2","first-page":"CD014884","article-title":"Intravenous immunoglobulin for the treatment of Kawasaki disease","volume":"1","author":"Broderick C","year":"2023","unstructured":"Broderick C, Kobayashi S, Suto M, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease. Cochrane Database Syst Rev 2023; 1(1): CD014884.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-012-1940-5"},{"issue":"4","key":"e_1_3_4_58_2","first-page":"CD006191","article-title":"Intravenous immunoglobulin for juvenile idiopathic arthritis","author":"Orellana JC","year":"2006","unstructured":"Orellana JC, Pogonza RE, Lopez\u2010Olivo MA, et al. Intravenous immunoglobulin for juvenile idiopathic arthritis. Cochrane Database Syst Rev 2006; 4: CD006191.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.4.421"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev318"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/93.11.751"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/12.7.1497"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V8111788"},{"issue":"12","key":"e_1_3_4_64_2","first-page":"2491","article-title":"Aseptic meningitis as a side effect of intravenous immune gammaglobulin","volume":"24","author":"Lafferty TE","year":"1997","unstructured":"Lafferty TE, DeHoratius RJ, Smith JB. Aseptic meningitis as a side effect of intravenous immune gammaglobulin. J Rheumatol 1997; 24(12): 2491\u20132492.","journal-title":"J Rheumatol"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199201233260413"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1177\/096120339900800617"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.1.77"},{"issue":"6","key":"e_1_3_4_68_2","first-page":"673","article-title":"Vasculitis in systemic lupus erythematosus following intravenous immunoglobulin therapy","volume":"14","author":"Hashkes PJ","year":"1996","unstructured":"Hashkes PJ, Lovell DJ. Vasculitis in systemic lupus erythematosus following intravenous immunoglobulin therapy. Clin Exp Rheumatol 1996; 14(6): 673\u2013675.","journal-title":"Clin Exp Rheumatol"}],"container-title":["Lupus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09612033251319402","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09612033251319402","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09612033251319402","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:28:40Z","timestamp":1777678120000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09612033251319402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1177\/09612033251319402"],"URL":"https:\/\/doi.org\/10.1177\/09612033251319402","relation":{},"ISSN":["0961-2033","1477-0962"],"issn-type":[{"value":"0961-2033","type":"print"},{"value":"1477-0962","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]}}}